GSK and the Pan-Canadian Pharmaceutical Alliance (pCPA) Agree to a LOetter of Intent (LOI) for Ojjaara for the Treatment of Myelofibrosis in Adults Who Have Moderate to Severe Anemia
MISSISSAUGA, ONTARIO- GSK announced that it successfully entered into a letter of intent (LOI) with the with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ojjaara (momelotinib) for the treatment of myelofibrosis in… Read More




